EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care DA VINCI

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/31479
• EU PAS number:
  EUPAS22075
• Study ID:
  31479
• Official title and acronym:
  EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care DA VINCI
• DARWIN EU® study:
  No
• Study countries:
  Austria

  Belgium

  Czechia

  Denmark

  France

  Germany

  Greece

  Hungary

  Ireland

  Italy

  Netherlands

  Poland

  Romania

  Slovakia

  Spain

  Sweden

  Ukraine

  United Kingdom
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Amgen

Multiple centres: 153 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 17/11/2016

Actual: 17/11/2016

Study start date

Planned: 01/06/2017

Actual: 01/06/2017

Data analysis start date

Planned: 22/02/2019

Actual: 22/02/2019

Date of final study report

Planned: 19/09/2019

Actual: 16/08/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen Ltd.

Study protocol

Initial protocol

EUPAS22075-23671

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable